An in vivo study using transplanted mice with leukemic cells carrying the homozygous TET2 loss with the Flt3ITD mutation demonstrated that an azacytidine treatment resulted in the normalized hypermethylated state of leukemic genome, as well as nearly the complete elimination of leukemic blasts, suggesting that TET2-mutated AML may be specifically responsive to HMAs [90]. This evidence concerns the gene TET2 and acute myeloid leukemia.